Free Trial
NASDAQ:ALBT

Avalon GloboCare (ALBT) Stock Price, News & Analysis

Avalon GloboCare logo
$3.13
-0.20 (-6.01%)
(As of 10/31/2024 ET)

About Avalon GloboCare Stock (NASDAQ:ALBT)

Key Stats

Today's Range
$2.90
$3.36
50-Day Range
$2.64
$5.49
52-Week Range
$2.42
$21.60
Volume
107,176 shs
Average Volume
173,582 shs
Market Capitalization
$3.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.

Avalon GloboCare Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
8th Percentile Overall Score

ALBT MarketRank™: 

Avalon GloboCare scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avalon GloboCare is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avalon GloboCare is -2.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Avalon GloboCare's valuation and earnings.
  • Percentage of Shares Shorted

    3.49% of the float of Avalon GloboCare has been sold short.
  • Short Interest Ratio / Days to Cover

    Avalon GloboCare has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avalon GloboCare has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Avalon GloboCare does not currently pay a dividend.

  • Dividend Growth

    Avalon GloboCare does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.49% of the float of Avalon GloboCare has been sold short.
  • Short Interest Ratio / Days to Cover

    Avalon GloboCare has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avalon GloboCare has recently increased by 8.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Avalon GloboCare has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Avalon GloboCare this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    Only 2 people have added Avalon GloboCare to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avalon GloboCare insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    37.30% of the stock of Avalon GloboCare is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 1.42% of the stock of Avalon GloboCare is held by institutions.

  • Read more about Avalon GloboCare's insider trading history.
Receive ALBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avalon GloboCare and its competitors with MarketBeat's FREE daily newsletter.

ALBT Stock News Headlines

Avalon GloboCare Corp. (NASDAQ:ALBT) Short Interest Update
The most productive 1 min of your day…
This next step in your trading career is a simple, yet important one. I want you to take 1 minute to sign up for FREE algo alerts powered by StocksToTrade.
Avalon Globocare Corp trading halted, news pending
Avalon GloboCare Collaborates for Cannabis Breathalyzer Development
Avalon announces 1-for-15 reverse stock split
See More Headlines

ALBT Stock Analysis - Frequently Asked Questions

Avalon GloboCare's stock was trading at $7.2450 at the beginning of 2024. Since then, ALBT shares have decreased by 56.8% and is now trading at $3.13.
View the best growth stocks for 2024 here
.

Avalon GloboCare Corp. (NASDAQ:ALBT) announced its quarterly earnings results on Monday, August, 19th. The company reported ($2.85) EPS for the quarter. The business had revenue of $0.33 million for the quarter.

Shares of Avalon GloboCare reverse split on the morning of Monday, October 28th 2024. The 1-15 reverse split was announced on Thursday, October 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of ALBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avalon GloboCare investors own include Sangamo Therapeutics (SGMO), Ford Motor (F), Pfizer (PFE), Plug Power (PLUG), NVIDIA (NVDA), Mullen Automotive (MULN) and Intel (INTC).

Company Calendar

Last Earnings
8/19/2024
Today
10/31/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALBT
Previous Symbol
NASDAQ:AVCO
Employees
5
Year Founded
N/A

Profitability

Net Income
$-16,710,000.00
Net Margins
-1,122.78%
Pretax Margin
-1,122.78%

Debt

Sales & Book Value

Annual Sales
$1.30 million
Book Value
($1.15) per share

Miscellaneous

Free Float
10,022,000
Market Cap
$36.98 million
Optionable
Not Optionable
Beta
0.31
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:ALBT) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners